Results 11 to 20 of about 11,877,029 (313)

Development and validation of a stability-indicating HPLC

open access: yesPakistan Journal of Pharmaceutical Sciences, 2023
Fosaprepitant dimeglumine, an injectable phosphorylated prodrug of aprepitant, has been approved for preventing chemotherapy-induced nausea and vomiting.
Lili Huang   +7 more
doaj   +1 more source

Scavenger receptor A-mediated nanoparticles target M1 macrophages for acute liver injury

open access: yesAsian Journal of Pharmaceutical Sciences, 2023
Acute liver injury (ALI) has an elevated fatality rate due to untimely and ineffective treatment. Although, schisandrin B (SchB) has been extensively used to treat diverse liver diseases, its therapeutic efficacy on ALI was limited due to its high ...
Rongping Zhang   +10 more
doaj   +1 more source

Efficacy of Intra-Articular Injection of Botulinum Toxin Type A (IncobotulinumtoxinA) in Temporomandibular Joint Osteoarthritis: A Three-Arm Controlled Trial in Rats

open access: yesToxins, 2023
Temporomandibular disorders (TMD) are complex pathologies responsible for chronic orofacial pain. Intramuscular injection of botulinum toxin A (BoNT/A) has shown effectiveness in knee and shoulder osteoarthritis, as well as in some TMDs such as ...
Marie Béret   +6 more
doaj   +1 more source

Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor‐associated macrophages

open access: yesActa Pharmaceutica Sinica B, 2023
As known, the benefits of photothermal therapy (PTT) are greatly limited by the heat tolerance of cancer cells resulting from overexpressed heat shock proteins (HSPs). Then HSPs further trigger the formation of stress granules (SGs) that regulate protein
Fan Tong   +11 more
doaj   +1 more source

An in situ dual-anchoring strategy for enhanced immobilization of PD-L1 to treat autoimmune diseases

open access: yesNature Communications, 2023
Immune checkpoints play key roles in maintaining self-tolerance. Targeted potentiation of the checkpoint molecule PD-L1 through in situ manipulation offers clinical promise for patients with autoimmune diseases.
Shenqiang Wang   +9 more
doaj   +1 more source

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome

open access: yesActa Pharmaceutica Sinica B, 2023
Intelligent responsive drug delivery system opens up new avenues for realizing safer and more effective combination immunotherapy. Herein, a kind of tumor cascade-targeted responsive liposome (NLG919@Lip-pep1) is developed by conjugating polypeptide ...
Chuan Hu   +8 more
doaj   +1 more source

Polysaccharide drug delivery systems based on pectin and chitosan [PDF]

open access: yes, 2010
Chitosans and pectins are natural polysaccharides which show great potential in drug delivery systems. Chitosans are a family of strongly polycationic derivatives of poly-N-acetyl-D-glucosamine.
Kok, M. S.   +3 more
core   +3 more sources

A Promising Drug Delivery: Intranasal Drug Delivery System

open access: yesInternational Journal of Pharmaceutical Sciences Review and Research, 2021
Pneumonic medication conveyance has acquired gigantic logical interest as of late and has advanced inside the setting of treatment for lung infections. Lung is an appealing climate for bio particles, which are exceptionally presented to enzymatic debasement in the gastrointestinal parcel just as hepatic corruption.
M. Srinivas, Y. Kalyani, J. V. C. Sharma
openaire   +1 more source

Release of functional dexamethasone by intracellular enzymes: A modular peptide-based strategy for ocular drug delivery [PDF]

open access: yes, 2020
Tissue barriers limit drug delivery in the eye. Therefore, retinal diseases are treated with intravitreal injections. Delivery systems with reduced dosing frequency and/or cellular drug delivery properties are needed.
Sadeghi, Amir   +7 more
core   +1 more source

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to prime an ...
Stefanie R. Mullins   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy